No completed randomized controlled human trial
What makes BPC-157 distinctive among research peptides is a combination of three properties rarely found together: it has no sequence homology to any other known peptide, it is completely stable in human gastric acid for at least 24 hours (unlike most growth factors and peptide analogues, which are rapidly degraded), and it remains active across an exceptionally broad effective dose range from nanogram to microgram per kilogram bodyweight in pre-clinical models without any known toxic dose having been established in animal studies to date
Consulting with a healthcare provider, such as through telehealth services like Doctronic.ai, ensures personalized and safe dosing guidance
GBM, a most frequent and aggressive subtype of glioma, comprises up to 50% of cases, originating from glial cells and can arise spontaneously as primary GBM or develop from a lower-grade or anaplastic astrocytoma, termed secondary GBM [41,42,43,44,45]